Actinium Pharmaceuticals Inc (ATNM)
8.73
-0.17
(-1.91%)
USD |
NYAM |
May 10, 16:00
8.73
0.00 (0.00%)
After-Hours: 20:00
Actinium Pharmaceuticals Cash from Operations (TTM): -39.63M for March 31, 2024
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
Date | Value |
---|---|
March 31, 2024 | -39.63M |
December 31, 2023 | -47.34M |
September 30, 2023 | -47.62M |
June 30, 2023 | -42.21M |
March 31, 2023 | -0.652M |
December 31, 2022 | 8.644M |
September 30, 2022 | 11.37M |
June 30, 2022 | 11.50M |
March 31, 2022 | -21.00M |
December 31, 2021 | -20.87M |
September 30, 2021 | -22.07M |
June 30, 2021 | -21.48M |
March 31, 2021 | -21.40M |
December 31, 2020 | -21.62M |
September 30, 2020 | -20.37M |
June 30, 2020 | -20.97M |
March 31, 2020 | -21.83M |
December 31, 2019 | -21.46M |
September 30, 2019 | -20.74M |
June 30, 2019 | -21.75M |
March 31, 2019 | -20.60M |
December 31, 2018 | -20.57M |
September 30, 2018 | -19.45M |
June 30, 2018 | -18.71M |
March 31, 2018 | -21.64M |
Date | Value |
---|---|
December 31, 2017 | -21.55M |
September 30, 2017 | -22.63M |
June 30, 2017 | -22.33M |
March 31, 2017 | -21.41M |
December 31, 2016 | -20.79M |
September 30, 2016 | -20.51M |
June 30, 2016 | -18.44M |
March 31, 2016 | -17.49M |
December 31, 2015 | -18.54M |
September 30, 2015 | -19.63M |
June 30, 2015 | -20.37M |
March 31, 2015 | -17.67M |
December 31, 2014 | -14.35M |
September 30, 2014 | -10.65M |
June 30, 2014 | -8.027M |
March 31, 2014 | -6.471M |
December 31, 2013 | -6.292M |
September 30, 2013 | -6.365M |
June 30, 2013 | -6.678M |
March 31, 2013 | -6.577M |
December 31, 2012 | -5.213M |
September 30, 2012 | -4.318M |
June 30, 2012 | -2.385M |
March 31, 2012 | -1.461M |
December 31, 2011 | -0.5176M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (TTM) Range, Past 5 Years
-47.62M
Minimum
Sep 2023
11.50M
Maximum
Jun 2022
-20.08M
Average
-21.43M
Median
Cash from Operations (TTM) Benchmarks
Perspective Therapeutics Inc | -36.91M |
Eli Lilly and Co | 3.676B |
Cellectar Biosciences Inc | -32.38M |
Outlook Therapeutics Inc | -47.10M |
Bristol-Myers Squibb Co | 13.72B |